A practical reference on WADA prohibited list: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-03 and is reviewed periodically as new material appears.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
== Preparation and structure == The parent compound can be prepared by heating urea at 150 °C for ~6 hours until it gets slightly cloudy, then recrystallizing from water. After that, it can be recrystallized repeatedly from 2% sodium hydroxide solution and water to finally get base-free crystalline needles of the monohydrate which are free of cyanuric acid. While heating, a lot of ammonia is expelled:
== Metabolism == Metabolic activation is required for PhIP to function as a mutagen. Therefore, the cancer risk posed by PhIP depends on the extent at which PhIP is metabolized. After absorption, PhIP is converted to a genotoxic metabolite in the liver by Phase I enzyme N-oxidation by Cytochrome P-450 1A2 (CYP1A2). PhIP can be further metabolized into a more potent metabolite through O-acetylation by hepatic or colonic N-acetyltransferase 1 (NAT1) and N-acetyltransferase 2 (NAT2), or by sulfotransferases. However, PhIP may also undergo a detoxification pathway through Phase II conjugation reaction via UDP-glucuronosyltransferases (UGTs) to form N-glucuronide conjugates. PhIP's nitrenium ion intermediate is a powerful electrophile that has propensity to form C-8 guanine adducts with the DNA. In addition, some of these metabolic enzymes are inducible and have polymorphic variation. CYP1A2 displays a 40-fold variation in expression among humans and can be induced by smoking, diet, and chronic hepatitis. The expression of UGTs also displays inducibility; however, NATs do not. Individuals can be classified as either rapid or slow N-oxidizers and O-acetylators by assessing CYP1A2 and NAT2 activities. Individuals with the rapid phenotype of either CYP1A2 or NAT2 metabolize PhIP more effectively and are therefore at greater risk of PhIP's carcinogenic metabolite and could be at a higher risk of cancer.
Malaysia signed the Rio Convention on Biological Diversity on 12 June 1993, and became a party to the convention on 24 June 1994. It has subsequently produced a National Biodiversity Strategy and Action Plan, which was received by the convention on 16 April 1998. The country is megadiverse with a high number of species and high levels of endemism. It is estimated to contain 20% of the world's animal species. High levels of endemism are found on the diverse forests of Borneo's mountains, as species are isolated from each other by lowland forest. There are about 210 mammal species in the country. Over 620 species of birds have been recorded in Peninsular Malaysia, with many endemic to the mountains there. A high number of endemic bird species are also found in Malaysian Borneo. 250 reptile species have been recorded in the country, with about 150 species of snakes and 80 species of lizards. There are about 150 species of frogs, and thousands of insect species. The Exclusive economic zone of Malaysia is 334,671 km2 (129,217 sq mi) and 1.5 times larger than its land area. It is mainly in the South China Sea. Some of its waters are in the Coral Triangle, a biodiversity hotspot. The waters around the island of Sipadan are the most biodiverse in the world. Bordering East Malaysia, the Sulu Sea is a biodiversity hotspot, with around 600 coral species and 1200 fish species. The unique biodiversity of Malaysian Caves always attracts lovers of ecotourism from all over the world. Nearly 4,000 species of fungi, including lichen-forming species, have been recorded from Malaysia.
== Assays for DBH activity in human serum and cerebrospinal fluid == DBH activity in human serum could be estimated by a spectrophotometric method or with the aid of ultra-high-performance liquid chromatography with photo diode array detector (UHPLC-PDA). A sensitive assay for the detection of DBH activity in cerebrospinal fluid using high-performance liquid chromatography with electrochemical detector (HPLC-ECD) was also described earlier.
classical genetics The branch of genetics based solely on observation of the visible results of reproductive acts, as opposed to that made possible by the modern techniques and methodologies of molecular biology. Contrast molecular genetics.
Sources: en.wikipedia.org
During most of the post-war era, democratic socialist, labourist and social-democratic parties dominated the political scene and laid the ground to universalistic welfare states in the Nordic countries. For much of the mid- and late 20th century, Sweden was governed by the Swedish Social Democratic Party largely in cooperation with trade unions and industry. Tage Erlander was the leader of the Social Democratic Party and led the government from 1946 until 1969, an uninterrupted tenure of twenty-three years, one of the longest in any democracy. From 1945 until 1962, the Norwegian Labour Party held an absolute majority in the parliament led by Einar Gerhardsen, who served Prime Minister for seventeen years. The Danish Social Democrats governed Denmark for most of the 20th century and since the 1920s and through the 1940s and the 1970s a large majority of Prime Ministers were members of the Social Democrats, the largest and most popular political party in Denmark.
Nutrition science (theoretical focus) and dietetics (practical focus) is the study of the relationship of food and drink to health and disease, especially in determining an optimal diet. Medical nutrition therapy is done by dietitians and is prescribed for diabetes, cardiovascular diseases, weight and eating disorders, allergies, malnutrition, and neoplastic diseases. Pathology as a science is the study of disease – the causes, course, progression and resolution thereof. Pharmacology is the study of drugs and their actions. Photobiology is the study of the interactions between non-ionizing radiation and living organisms. Physiology is the study of the normal functioning of the body and the underlying regulatory mechanisms. Radiobiology is the study of the interactions between ionizing radiation and living organisms. Toxicology is the study of hazardous effects of drugs and poisons.
N,N′-Dicyclohexylcarbodiimide (DCC or DCCD) is an organic compound with the chemical formula (C6H11N)2C. It is a waxy white solid with a sweet odor. Its primary use is to couple amino acids during artificial peptide synthesis. The low melting point of this material allows it to be melted for easy handling. It is highly soluble in dichloromethane, tetrahydrofuran, acetonitrile and dimethylformamide, but insoluble in water.
== Clinical significance == A better understanding of the mechanisms of collagen fibrillogenesis as well as an understanding of the regulators of the process would allow for a better understanding of diseases that affect collagen fibril formation and assembly such as Ehlers-Danlos syndromes (EDS). On a broader spectrum, an understanding of the processes that lie behind fibrillogenesis would allow for great advancements in the field of regenerative medicine. A greater understanding would lead to a potential future in which organs and tissue damaged through trauma could be regenerated using the basis of collagen fibrillogenesis.
== Structure == Hyaline cartilage is the most common kind of cartilage in the human body. It is primarily composed of type II collagen and proteoglycans. Hyaline cartilage is located in the trachea, nose, epiphyseal plate, sternum, and ribs. Hyaline cartilage is covered externally by a fibrous membrane known as the perichondrium. The primary cells of cartilage are chondrocytes, which are in a matrix of fibrous tissue, proteoglycans and glycosaminoglycans. As cartilage does not have lymph glands or blood vessels, the movements of solutes, including nutrients, occur via diffusion within the fluid compartments contiguous with adjacent tissues. Cartilage gives the structures a definite but pliable form, making them strong, but with limited mobility and flexibility. Cartilage has no nerves. Hyaline cartilage also forms the temporary embryonic skeleton, which is gradually replaced by bone, and the skeleton of elasmobranch fish.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.